India's Glenmark To Study Potential COVID-19 Drug Combination

India's Glenmark To Study Potential COVID-19 Drug Combination

May 26, 2020, 5:57 p.m.

Glenmark Pharmaceuticals Ltd said it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir - as a potential COVID-19 treatment.

Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while umifenovir is licensed as a treatment of some types of flu infections in Russia and China.

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.

More on Health

The Latest

Latest Magazine

VOL. 15, No. 01, July 16, 2021 (Shrawan 1, 2078) Publisher and Editor: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 14, No. 20, July 2, 2021 (Asadh 18, 2078) Publisher and Editor: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 14, No. 19, June 18, 2021 (Asadh 4, 2078) Publisher: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 14, No. 18, June 04, 2021 (Jestha 21, 2078) Publisher: Keshab Prasad Poudel Online Register Number: DOI 584/074-75